60.29
+1.75
+(2.99%)
At close: 4:00:00 PM EDT
59.97
-0.32
(-0.53%)
After hours: 5:10:23 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David S. Zaccardelli Pharm.D. | President, CEO & Executive Director | 1.37M | -- | 1964 |
| Mr. Mark W. Hahn | Chief Financial Officer | 915.91k | -- | 1963 |
| Mr. Andrew Fisher | General Counsel | 596.93k | -- | 1971 |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer | 726k | -- | 1958 |
| Ms. Victoria Stewart | Senior Director of Investor Relations & Communications | -- | -- | -- |
| Mr. Matthew Casbon | VP of Sales, Marketing & Training | -- | -- | -- |
| Ms. Ostra Jewell | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer | -- | -- | 1976 |
| Mr. Christopher Martin | Chief Commercial Officer | -- | -- | -- |
| Ms. Caroline Diaz | Chief Regulatory Officer | -- | -- | -- |
Verona Pharma plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 209
Description
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Corporate Governance
Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Verona Pharma plc Earnings Date
Recent Events
Related Tickers
EWTX Edgewise Therapeutics, Inc.
15.52
-22.90%
SRRK Scholar Rock Holding Corporation
32.54
+8.25%
MDGL Madrigal Pharmaceuticals, Inc.
334.60
+3.28%
BBIO BridgeBio Pharma, Inc.
34.62
+4.85%
CYTK Cytokinetics, Incorporated
40.25
+7.33%
INSM Insmed Incorporated
73.44
+2.00%
AXSM Axsome Therapeutics, Inc.
109.75
-1.72%
SWTX SpringWorks Therapeutics, Inc.
46.52
+11.08%
WVE Wave Life Sciences Ltd.
7.57
-2.20%
RNA Avidity Biosciences, Inc.
29.77
+11.33%